Jupiter Neurosciences attaches 8-K after director resignation

Jupiter Neurosciences, Inc. filed a Prospectus Supplement No. 6 to its Registration Statement (No. 333-291832) dated June 22, 2026, which incorporates its Form 8-K dated June 17, 2026.

Rhea-AI Filing Summary

Jupiter Neurosciences, Inc. filed a Prospectus Supplement No. 6 to its Registration Statement (No. 333-291832) dated June 22, 2026, which incorporates its Form 8-K dated June 17, 2026. The Form 8-K reports that director Allison W. Brady resigned from the Board and from the Audit and Compensation Committees, effective June 17, 2026. Her Board seat will remain vacant until the annual meeting on July 22, 2026. The supplement references the Prospectus dated December 11, 2025 and notes the company’s Nasdaq symbol JUNS and a closing share price of $0.2380 on June 18, 2026.

Insights

Corporate Governance Analyst

Board resignation creates a temporary vacancy ahead of the July annual meeting.

The filing states that Allison W. Brady resigned from the Board and two committees effective June 17, 2026. The company will leave the seat vacant until the annual meeting on July 22, 2026.

Governance implications depend on quorum and committee coverage; subsequent disclosure at the annual meeting or a later 8-K should identify any replacement or interim committee assignments.

Equity Capital Markets Specialist

Prospectus supplement attaches an 8-K update while preserving the December 11, 2025 prospectus.

The supplement (No. 6) to the Registration Statement No. 333-291832 incorporates the Form 8-K dated June 17, 2026. It restates Nasdaq listing (symbol JUNS) and cites a closing price of $0.2380 on June 18, 2026.

Cash-flow and offering amounts are not disclosed in the excerpt; further prospectus or supplement pages would be required for offering terms.

Key Figures

Registration Number: 333-291832 Closing Price: $0.2380 Prospectus Date: December 11, 2025 +3 more

6 metrics

Registration Number 333-291832 Registration Statement covering the prospectus

Closing Price $0.2380 Closing price on June 18, 2026

Prospectus Date December 11, 2025 Date of the base prospectus referenced by the supplement

Form 8-K Date June 17, 2026 Date of the Current Report attached to the supplement

Director Resignation Date June 17, 2026 Effective date of Allison W. Brady’s resignation

Annual Meeting Date July 22, 2026 Date when the Board seat will be addressed

Key Terms

Prospectus Supplement, Form 8-K, Registration Statement

3 terms

Prospectus Supplement regulatory

"This prospectus supplement updates, amends and supplements the prospectus dated December 11, 2025"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

Form 8-K regulatory

"This prospectus supplement is being filed to update, amend and supplement the information included in the Prospectus with information contained in our Current Report on Form 8-K"

A Form 8-K is a report that companies file with the government to share important news quickly, such as changes in leadership, major business deals, or financial updates. It matters because it helps investors stay informed about significant events that could affect the company's value or stock price.

Registration Statement regulatory

"which forms a part of our Registration Statement on Form S-1 (Registration No. 333-291832)"

A registration statement is a formal document that companies file with a government agency to offer new shares of stock to the public. It provides essential information about the company's finances, operations, and risks, helping investors make informed decisions. Think of it as a detailed product description that ensures transparency and trust before buying into a company.

Offering Details

base_shelf_indeterminate

Offering

Offering Type base_shelf_indeterminate

Securities Offered Common Stock

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Jupiter Neurosciences (JUNS) disclose in Prospectus Supplement No. 6?

The supplement attaches a Current Report on Form 8-K and updates the prospectus. It incorporates the Form 8-K dated June 17, 2026 and supplements the Prospectus dated December 11, 2025, per the filing dated June 22, 2026.

Who resigned from Jupiter Neurosciences' board in the filing?

Director Allison W. Brady resigned from the Board and from the Audit and Compensation Committees, effective June 17, 2026, and the company says the resignation was not due to any disagreement with the company’s operations or policies.

Will Jupiter Neurosciences fill the vacant board seat immediately?

The filing states the Board seat will remain vacant until the annual meeting on July 22, 2026. The company did not disclose any interim appointment or a planned replacement timing in the provided excerpt.

What market detail does the supplement include about JUNS shares?

The supplement notes that Jupiter Neurosciences’ common stock trades on Nasdaq under JUNS and reports a closing price of $0.2380 per share on June 18, 2026 as stated in the prospectus supplement.

Does the prospectus supplement change offering terms or amounts?

The supplement updates the prospectus by attaching the Form 8-K; the excerpt does not provide any offering size, price range, or use‑of‑proceeds details, so no offering terms are disclosed in the provided text.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/22/2026 - 07:32 AM EDT Learn about SEC filing dates

Filed pursuant to Rule 424(b)(3)

Registration No. 333-291832

Prospectus Supplement No. 6

(To Prospectus dated December 11, 2025)

Jupiter Neurosciences, Inc.

This prospectus supplement updates, amends and supplements the prospectus dated December 11, 2025 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-291832) and is being filed to update, amend and supplement the information included in the Prospectus with information contained in our Current Report on Form 8-K, which was filed with the Securities and Exchange Commission (the “SEC”) on June 22, 2026 (the “Current Report”). Accordingly, we have attached the Current Report to this prospectus supplement. Capitalized terms used in this prospectus supplement and not otherwise defined herein have the meanings specified in the Prospectus.

This prospectus supplement is not complete without the Prospectus. This prospectus supplement should be read in conjunction with the Prospectus, which is to be delivered with this prospectus supplement, and is qualified by reference thereto, except to the extent that the information in this prospectus supplement updates or supersedes the information contained in the Prospectus. Please keep this prospectus supplement with your Prospectus for future reference.

Shares of our common stock, par value $0.0001 per share (our “Common Stock”), are listed on The Nasdaq Stock Market, LLC under the symbol “JUNS.” On June 18, 2026, the closing price of our Common Stock was $0.2380 per share.

Investing in our securities involves risks that are described in the “Risk Factors” section of the Prospectus.

Neither the SEC nor any state securities commission has approved or disapproved of the securities to be issued under the Prospectus or this prospectus supplement or determined if the Prospectus or this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense.

The date of this prospectus supplement is June 22, 2026.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

June 17, 2026

Date of Report (Date of earliest event reported)

JUPITER NEUROSCIENCES, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-41265		47-4828381
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

1001 North US HWY 1, Suite 504, Jupiter, FL		33477
(Address of principal executive offices)		(Zip Code)

(561) 406-6154

Registrant’s telephone number, including area code

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock		JUNS		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On June 17, 2026, Allison W. Brady, a member of the Board of Directors (the “Board”) of Jupiter Neurosciences, Inc. (the “Company”), informed the Company of her decision to resign from the Board, effective immediately. Ms. Brady also resigned from her positions as a member of the Audit Committee and the Compensation Committee of the Board, effective as of the same date. Her decision to resign is not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. Ms. Brady’s seat on the Board will remain vacant until the Company’s annual meeting on July 22, 2026.

Item 9.01. Financial Statements and Exhibits.

Exhibit No.		Description
104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	JUPITER NEUROSCIENCES, INC.
Date: June 22, 2026	By:	/s/ Christer Rosén
	Name:	Christer Rosén
	Title:	Chief Executive Officer